Next Article in Journal
A Marine Isolate of Bacillus pumilus Secretes a Pumilacidin Active against Staphylococcus aureus
Previous Article in Journal
The In Vitro Anti-Tumor Activity of Phycocyanin against Non-Small Cell Lung Cancer Cells
Article Menu

Export Article

Open AccessReview
Mar. Drugs 2018, 16(6), 179; https://doi.org/10.3390/md16060179

Developments of Cyanobacteria for Nano-Marine Drugs: Relevance of Nanoformulations in Cancer Therapies

1
Department of Energy and Materials Engineering, Dongguk University-Seoul, 30 Pildong-ro 1-gil, Seoul 04620, Korea
2
WCSL of Integrated Human Airway-on-a-chip, Department of Biological Engineering, Biohybrid Systems Research Center (BSRC), Inha University, 100 Inha-ro, Nam-gu, Incheon 22212, Korea
3
Department of Food Science and Technology, Yeungnam University, Gyeongsan-si, Gyeongsangbuk-do 38541, Korea
*
Authors to whom correspondence should be addressed.
Received: 28 February 2018 / Revised: 10 May 2018 / Accepted: 20 May 2018 / Published: 23 May 2018
View Full-Text   |   Download PDF [2077 KB, uploaded 23 May 2018]   |  

Abstract

Current trends in the application of nanomaterials are emerging in the nano-biotechnological sector for development of medicines. Cyanobacteria (blue-green algae) are photosynthetic prokaryotes that have applications to human health and numerous biological activities as dietary supplements. Cyanobacteria produce biologically active and chemically diverse compounds such as cyclic peptides, lipopeptides, fatty acid amides, alkaloids, and saccharides. More than 50% of marine cyanobacteria are potentially exploitable for the extraction of bioactive substances, which are effective in killing cancer cells by inducing apoptotic death. The current review emphasizes that not even 10% of microalgal bioactive components have reached commercialized platforms due to difficulties related to solubility. Considering these factors, they should be considered as a potential source of natural products for drug discovery and drug delivery approaches. Nanoformulations employing a wide variety of nanoparticles and their polymerized forms could be an emerging approach to the development of new cancer drugs. This review highlights recent research on microalgae-based medicines or compounds as well as their biomedical applications. This review further discusses the facts, limitations, and commercial market trends related to the use of microalgae for industrial and medicinal purposes. View Full-Text
Keywords: microalgae/cyanobacteria; nanoformulation; drug development; commercial drawbacks microalgae/cyanobacteria; nanoformulation; drug development; commercial drawbacks
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Bajpai, V.K.; Shukla, S.; Kang, S.-M.; Hwang, S.K.; Song, X.; Huh, Y.S.; Han, Y.-K. Developments of Cyanobacteria for Nano-Marine Drugs: Relevance of Nanoformulations in Cancer Therapies. Mar. Drugs 2018, 16, 179.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top